En Carta Diagnostics vs Mammoth Biosciences
En Carta Diagnostics vs Mammoth Biosciences, compared side by side on 17 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: En Carta Diagnostics is on 52/100 and Mammoth Biosciences on 63/100.
Where each one leads
En Carta Diagnostics
Leads on none of the measures we hold for both companies.
Mammoth Biosciences
- our overall score: 63/100 against 52/100
- domain rating: 53/100 against 0/100
- headcount: 165 against 12
- funding raised: $460M against $5.0M
- LinkedIn following: 57,986 against 2,091
At a glance
| Measure | En Carta Diagnostics | Mammoth Biosciences |
|---|---|---|
| What it is | Developing a new generation of molecular diagnostics for at-home use, combining laboratory accuracy with rapid test simplicity. | Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics. |
| Category | Biotechnology, HealthTech, Diagnostics, Medical Devices | Biotechnology, Drug Discovery, Genomics, CRISPR Technology |
| Sells toBusiness model | B2B2C | B2B |
| Offering | Hardware | Platform |
| Founded | 2022 | 2017 |
| Headquarters | Paris, France | Brisbane, United States |
| Status | Inactive | Active |
Size, funding and growth
| Measure | En Carta Diagnostics | Mammoth Biosciences |
|---|---|---|
| Employees | 12 | 165 |
| Headcount growthLast 12 months | Not published | +5.8% |
| Total funding | $5.0M | $460M |
| Latest round | Seed | Funding Round |
| Valuation | Not published | $1.1B |
| LinkedIn followers | 2,091 | 57,986 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | En Carta Diagnostics | Mammoth Biosciences |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 52/100 | 63/100 |
| Traction | 45/100 | 60/100 |
| Team | 70/100 | 70/100 |
| Search visibility | 20/100 | 35/100 |
| Quality | 58/100 | 68/100 |
| Agent readinessHow well an AI agent can read and act on the site | Not published | F (35/100) |
| Domain ratingLink authority, 0-100 | 0/100 | 53/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | En Carta Diagnostics | Mammoth Biosciences |
|---|---|---|
| CMS | Not detected | WordPress |
| Frameworks | Not detected | Jquery |
| Analytics | Not detected | Google Analytics 4 |
En Carta Diagnostics vs Mammoth Biosciences: common questions
Which is better, En Carta Diagnostics or Mammoth Biosciences?
On our 0-100 score Mammoth Biosciences rates higher (63/100 against 52/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 17 data points above: read the rows that match what you are buying for.
How do En Carta Diagnostics and Mammoth Biosciences compare on the numbers?
Mammoth Biosciences leads on our overall score (63/100 against 52/100), domain rating (53/100 against 0/100), headcount (165 against 12), funding raised ($460M against $5.0M), LinkedIn following (57,986 against 2,091).
Read the full En Carta Diagnostics review and pricing or the Mammoth Biosciences review and pricing. You can also browse other En Carta Diagnostics alternatives we track.